Skip to main content
. 2017 Oct 12;1(11):1351–1361. doi: 10.1210/js.2017-00332

Table 2.

OGTT Data of the Subjects Whose Genetic Analyses Were Performed, Excluding Case 5 and Case 11

Characteristic Time, min
Glycemic Status
0 30 60 120 180 240 300
Case 1 Diabetes
 Glucose (mg/dL) 103 222 270 236 135 87 46a
 IRI (µU/mL) 17.7 62.4 108.2 210.8b 133.7 79.1 7.7
Case 2 IGT
 Glucose (mg/dL) 114 174 184 163 73a 77 90
 IRI (µU/mL) 27.5 118 178.3 178.4b 25.5 10.1 10.5
Case 3 NGT
 Glucose (mg/dL) 91a 154 134 114 93
 IRI (µU/mL) 9.1 158.7 232.8b 42.5 35.7
Case 4 IGT
 Glucose (mg/dL) 96 121 178 150 127 50a 80
 IRI (µU/mL) 15.9 68.3 111.6 113.3b 108.5 14.5 8.1
Case 6 NGT
 Glucose (mg/dL) 96 214 188 83 72a 81 84
 IRI (µU/mL) 24.1 423.0b 387.0 110.3 22.5 13.1 24.0
Case 7 IGT
 Glucose (mg/dL) 108 214 243 182 92 62a 81
 IRI (µU/mL) 30.3 207.5 269.8 279.1b 101.3 32.4 20.9
Case 8 IGT
 Glucose (mg/dL) 96 171 193 176 92 52a 75
 IRI (µU/mL) 11.0 68.9 86.5 196.5b 71.9 9.5 9.1
Case 9 IGT
 Glucose (mg/dL) 87a 152 130 148 121
 IRI (µU/mL) 8.8 79.0b 55.4 72.8 53.1
Case 10 NGT
 Glucose (mg/dL) 100 164 159 113 75a 88 91
 IRI (µU/mL) 19.7 180.9 198.9b 142.7 28.7 15.7 17.8

Abbreviations: IGT, impaired glucose tolerance; IRI, immunoreactive insulin; NGT, normal glucose tolerance.

a

Minimum glucose level.

b

Peak immunoreactive insulin level.

HHS Vulnerability Disclosure